drugset / Trial / NCT00917358
Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C
Phase 4
Completed
42 enrolled
National Taiwan University Hospital
National Science and Technology Council, Taiwan · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Interferon-based monotherapy has been considered effective to treat acute hepatitis C in ordinary patients. However, the efficacy of this treatment has not been evaluated in prospective interventional studies for dialysis patients. The aim of the study is the evaluate the efficacy of peginterferon alfa-2a monotherapy for 24 weeks in this special clinical setting, and concomitantly evaluate retrospectively the dialysis patients with acute hepatitis C who did not receive intervention as the reference.
Timeline
- Start
- 2005-07
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 135 ug | — |